GlassScriptPhysician profile
Tian Cheng Zhou
NPI 1750624334
$6,581.07
in general payments reported to CMS, 2019-2025
37 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $148 · 2021: $280 · 2022: $829 · 2023: $826 · 2024: $1,090 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,502.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,473.89 | 2019 | |
| Astellas Pharma US INC | $745.16 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $700.78 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $679.56 | 2019-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $412.98 | 2019-2025 | |
| Coloplast Corp | $284.18 | 2023-2025 | Speedicath |
| Merck Sharp & Dohme LLC | $255.14 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $217.87 | 2019-2025 | |
| Urogen Pharma, INC. | $198.25 | 2023-2025 | Jelmyto |
| Tolmar, INC. | $172.31 | 2023-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $154.92 | 2019-2025 | Adstiladrin |
| Urovant Sciences INC | $122.44 | 2022 | |
| Myriad Genetic Laboratories, INC. | $106.14 | 2024-2025 | Prolaris |
| Dendreon Pharmaceuticals LLC | $94.74 | 2019-2023 | Provenge |
| Endo USA, INC. | $94.22 | 2024-2025 | Xiaflex, Aveed |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $91.94 | 2019-2022 | |
| Teleflex LLC | $87.77 | 2025 | Urolift, Barrigel |
| Progenics Pharmaceuticals, INC. | $83.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $80.13 | 2025 | |
| 180 Medical, INC. | $57.10 | 2022-2023 | Gentlecath |
| Blue Earth Diagnostics | $52.84 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $44.18 | 2023-2024 | Xiaflex, Aveed, Edex |
| Hollister Incorporated | $39.10 | 2022-2023 | Vapro Pocket |
| Astrazeneca Pharmaceuticals LP | $38.08 | 2025 | Lokelma |
| Procept Biorobotics Corporation | $37.38 | 2024 | Aquabeam System |
| Tolmar Pharmaceuticals, INC. | $33.51 | 2022 | |
| Myovant Sciences INC. | $27.91 | 2022 | |
| Amgen INC. | $26.58 | 2020 | |
| Axonics, INC. | $24.25 | 2023 | Axonics, Bulkamid |
| Dentsply Ih Ab | $21.48 | 2023 | Lofric |
| Abc Home Medical Supply, INC. | $19.98 | 2025 | |
| Telix Pharmaceuticals | $19.94 | 2024 | Illuccix |
| Medtronic USA, INC. | $18.19 | 2020 | |
| Sun Pharmaceutical Industries INC. | $18.18 | 2025 | |
| Calyxo, INC. | $17.89 | 2025 | Cvac Aspiration System |
| Dentsply Ih INC. | $15.42 | 2021 | |
| Accord Healthcare, INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tian Cheng Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.